SCCM Resource Library-Recognition and Management of HLH in the Context of Cellular Therapy

Recognition and Management of HLH in the Context of Cellular Therapy

Video Transcription

Video Summary

The speaker discusses a case of an adult patient who developed HLH (hemophagocytic lymphohistiocytosis) after receiving CAR-T therapy. The patient had initially experienced cytokine release syndrome (CRS) and neurotoxicity but later developed worsening encephalopathy and laboratory abnormalities indicative of HLH. The speaker highlights the challenges in diagnosing HLH in this context and discusses the potential treatment options, including tocilizumab, steroids, anakinra, and imipalumab. The speaker emphasizes the importance of multidisciplinary care and notes the poor outcomes associated with CAR T-associated HLH. The speaker also mentions that there are currently no treatment guidelines specifically for this condition.

Asset Subtitle

Immunology, 2023

Asset Caption

Type: one-hour concurrent | Evolving Landscape in Critical Care Medicine: Cellular Therapy-Related Toxicity (SessionID 1202444)

Meta Tag

Content Type Presentation

Knowledge Area Immunology

Membership Level Professional

Membership Level Select

Tag Immunology

Year 2023

Keywords

HLH

CAR-T therapy

cytokine release syndrome

encephalopathy

treatment options

	Society of Critical Care Medicine 500 Midway Drive Mount Prospect, IL 60056 USA Phone: +1 847 827-6888 Fax: +1 847 439-7226 Email: support@sccm.org	Contact Us About SCCM Newsroom Advertising & Sponsorship DONATE	MySCCM LearnICU Patients & Families Surviving Sepsis Campaign Critical Care Societies Collaborative	GET OUR NEWSLETTER
© Society of Critical Care Medicine. All rights reserved. \| Privacy Statement \| Terms & Conditions The Society of Critical Care Medicine, SCCM, and Critical Care Congress are registered trademarks of the Society of Critical Care Medicine.